Abstract: The overall incidence rate of A181V/T mutation in genotype C (5.3%) was significantly higher than that in genotype B (0.4%) (x2=12.23, P less than 0.01), but the incidence rate of M204I/V, L180M, T184A/G/I/S, S202G/I and V173L mutations was not significantly different between genotype B and C (each P more than 0.05).
Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Introduction: Both patients were infected with HBV with M204V+L180M LVDr substitutions at study entry and developed additional substitutions T184G & S202I, or M250V on therapy.
Method: Additional HBV-RT homology models were constructed with the LVD (M204V+L180M) and adefovir (A181T/V and N236T) resistance substitutions
Result: Several different ETVr substitutions have been observed in ETV-treated patients, including T184A/C/F/G/I/L/M/S, S202C/G/I, and M250 I/L/V.
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
PMID: 19301976
2009
The Journal of infectious diseases
Method: Established NRTI-resistance mutations included the following RT mutations: rtL80V/I, rtI169T, rtV173L, rtL180M, rtA181TV, rtT184S/A/I/L/F/G, rtA194T, rtS202G/I, rtM204V/I/S, rtN236T, and rt PMID: 19669299
2008
Hepatology international
Abstract: Both pathways are associated with clusters of secondary mutations that can affect subsequent treatment with NAs (rtT184G, rtS202I) such as ETV.
Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Abstract: Prior to lamivudine treatment, three cases (2.7%) had substitutions in the HBV polymerase gene corresponding to variants associated with ETV resistance (rtS202S/I).
Abstract: The aim of this study was to determine the prevalence of HBV variants associated with ETV resistance (rtI169T, rtT184G, rtS202I, rtM250V) in naive patients before and during lamivudine therapy.
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
PMID: 15328117
2004
Antimicrobial agents and chemotherapy
Abstract: Reduced susceptibility in vitro was highest when both the rtT184G and the rtS202I changes were combined with the 3TC(r) substitutions.
Abstract: Viral rebound occurred after 76 weeks of therapy with ETV at 1.0 mg, with the emergence of rtT184G, rtI169T, and rtS202I substitutions within the preexisting 3TC(r) background.
HBV mutation literature information.
PMID: 
2010
Zhonghua gan zang bing za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT